This brand name is authorized in Tunisia
The drug LAPTOR contains one active pharmaceutical ingredient (API):
|
1
Atorvastatin
UNII A0JWA85V8F - ATORVASTATIN
|
|
Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase. Atorvastatin lowers plasma cholesterol and lipoprotein serum concentrations by inhibiting HMG-CoA reductase and subsequently cholesterol biosynthesis in the liver and increases the number of hepatic LDL receptors on the cell surface for enhanced uptake and catabolism of LDL. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| C10AA05 | Atorvastatin | C Cardiovascular system → C10 Lipid modifying agents → C10A Lipid modifying agents, plain → C10AA HMG CoA reductase inhibitors |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: TN | Direction de la Pharmacie et du Médicament | Identifier(s): 9373401, 9373402, 9373403, 9373404, 9373405, 9373406, 9373407, 9373408 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
